Robert M Prins

Summary

Affiliation: Cedars-Sinai Medical Center
Country: USA

Publications

  1. ncbi request reprint Irradiated tumor cell vaccine for treatment of an established glioma. II. Expansion of myeloid suppressor cells that promote tumor progression
    Robert M Prins
    Department of Anatomy, Virginia Commonwealth University Medical College of Virginia, 1101 E Marshall Street, P O Box 980709, MCV Station, Richmond, VA 23198 0709, USA
    Cancer Immunol Immunother 51:190-9. 2002
  2. ncbi request reprint Irradiated tumor cell vaccine for treatment of an established glioma. I. Successful treatment with combined radiotherapy and cellular vaccination
    Martin R Graf
    Department of Anatomy and Division of Neurosurgery, Virginia Commonwealth University Medical College of Virginia, 1101 E Marshall Street, P O Box 980709, Richmond, VA 23198 0709, USA
    Cancer Immunol Immunother 51:179-89. 2002
  3. ncbi request reprint Contrasting effects of interleukin-2 secretion by rat glioma cells contingent upon anatomical location: accelerated tumorigenesis in the central nervous system and complete rejection in the periphery
    Martin R Graf
    Department of Anatomy and Neurobiology, Medical College of Virginia, Virginia Commonwealth University, P O Box 980709 MCV Station, Richmond, VA 23298 0709, USA
    J Neuroimmunol 140:49-60. 2003
  4. ncbi request reprint Thymic function and output of recent thymic emigrant T cells during intracranial glioma progression
    Robert M Prins
    Department of Anatomy and Surgery, Virginia Commonwealth University Medical College of Virginia, Richmond, VA, USA
    J Neurooncol 64:45-54. 2003
  5. ncbi request reprint The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity
    Robert M Prins
    Division of Neurosurgery, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles UCLA, CA 90095, USA
    J Immunol 176:157-64. 2006
  6. ncbi request reprint Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment
    Linda M Liau
    Division of Neurosurgery, Department of Surgery, The Brain Research Institute, David Geffen School of Medicine at University of California at Los Angeles, University of California Los Angeles, Los Angeles, California 90095, USA
    Clin Cancer Res 11:5515-25. 2005
  7. ncbi request reprint Cellular immunity and immunotherapy of brain tumors
    Robert M Prins
    Division of Neurosurgery, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 6901, USA
    Front Biosci 9:3124-36. 2004
  8. ncbi request reprint Characterization of defective CD4-CD8- T cells in murine tumors generated independent of antigen specificity
    Robert M Prins
    Maxine Dunitz Neurosurgical Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Immunol 172:1602-11. 2004
  9. ncbi request reprint Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model
    Robert M Prins
    Department of Surgery Neurosurgery, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095 6901, USA
    Cancer Res 63:8487-91. 2003
  10. ncbi request reprint Central nervous system tumor immunity generated by a recombinant listeria monocytogenes vaccine targeting tyrosinase related protein-2 and real-time imaging of intracranial tumor burden
    Robert M Prins
    Division of Neurosurgery, Department of Surgery, David Geffen School of Medicine, UCLA, Los Angeles, California, USA
    Neurosurgery 58:169-78; discussion 169-78. 2006

Collaborators

Detail Information

Publications15

  1. ncbi request reprint Irradiated tumor cell vaccine for treatment of an established glioma. II. Expansion of myeloid suppressor cells that promote tumor progression
    Robert M Prins
    Department of Anatomy, Virginia Commonwealth University Medical College of Virginia, 1101 E Marshall Street, P O Box 980709, MCV Station, Richmond, VA 23198 0709, USA
    Cancer Immunol Immunother 51:190-9. 2002
    ..Therefore, we believe that an MSC population is responsible for inhibiting the anti-tumor T cell response, resulting in the enhanced growth of the i.c. glioma, and may represent a significant obstacle to immune-based therapies...
  2. ncbi request reprint Irradiated tumor cell vaccine for treatment of an established glioma. I. Successful treatment with combined radiotherapy and cellular vaccination
    Martin R Graf
    Department of Anatomy and Division of Neurosurgery, Virginia Commonwealth University Medical College of Virginia, 1101 E Marshall Street, P O Box 980709, Richmond, VA 23198 0709, USA
    Cancer Immunol Immunother 51:179-89. 2002
    ....
  3. ncbi request reprint Contrasting effects of interleukin-2 secretion by rat glioma cells contingent upon anatomical location: accelerated tumorigenesis in the central nervous system and complete rejection in the periphery
    Martin R Graf
    Department of Anatomy and Neurobiology, Medical College of Virginia, Virginia Commonwealth University, P O Box 980709 MCV Station, Richmond, VA 23298 0709, USA
    J Neuroimmunol 140:49-60. 2003
    ..F cells. Intracranial T9.F/IL2/#12 tumors were markedly infiltrated by CD4(+) and CD8(+) T cells, natural killer (NK)-T cells and myeloid progenitor cells, whereas subcutaneous T9.F/IL2/#12 tumors contained an elevated level of NK cells...
  4. ncbi request reprint Thymic function and output of recent thymic emigrant T cells during intracranial glioma progression
    Robert M Prins
    Department of Anatomy and Surgery, Virginia Commonwealth University Medical College of Virginia, Richmond, VA, USA
    J Neurooncol 64:45-54. 2003
    ..Our findings may shed light on the significance of thymic function for anti-glioma immunity and the response to immunotherapeutic treatment paradigms...
  5. ncbi request reprint The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity
    Robert M Prins
    Division of Neurosurgery, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles UCLA, CA 90095, USA
    J Immunol 176:157-64. 2006
    ..Nevertheless, immunotherapeutic targeting of malignant CNS tumors may be enhanced by the administration of the innate immune response modifier imiquimod...
  6. ncbi request reprint Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment
    Linda M Liau
    Division of Neurosurgery, Department of Surgery, The Brain Research Institute, David Geffen School of Medicine at University of California at Los Angeles, University of California Los Angeles, Los Angeles, California 90095, USA
    Clin Cancer Res 11:5515-25. 2005
    ..As a next step in vaccine development, a phase I clinical trial was established to evaluate this strategy for its feasibility, safety, and induction of systemic and intracranial T-cell responses in patients with glioblastoma multiforme...
  7. ncbi request reprint Cellular immunity and immunotherapy of brain tumors
    Robert M Prins
    Division of Neurosurgery, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 6901, USA
    Front Biosci 9:3124-36. 2004
    ..Finally, the current state of immune-based treatment paradigms and future directions will be discussed, paying particular attention to adoptive cellular immunotherapy and tumor vaccine approaches for the treatment of malignant gliomas...
  8. ncbi request reprint Characterization of defective CD4-CD8- T cells in murine tumors generated independent of antigen specificity
    Robert M Prins
    Maxine Dunitz Neurosurgical Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Immunol 172:1602-11. 2004
    ....
  9. ncbi request reprint Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model
    Robert M Prins
    Department of Surgery Neurosurgery, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095 6901, USA
    Cancer Res 63:8487-91. 2003
    ..These results suggest that shared MAAs on gliomas can be targeted immunotherapeutically, pointing the way to a new potential treatment option for patients with malignant gliomas...
  10. ncbi request reprint Central nervous system tumor immunity generated by a recombinant listeria monocytogenes vaccine targeting tyrosinase related protein-2 and real-time imaging of intracranial tumor burden
    Robert M Prins
    Division of Neurosurgery, Department of Surgery, David Geffen School of Medicine, UCLA, Los Angeles, California, USA
    Neurosurgery 58:169-78; discussion 169-78. 2006
    ....
  11. ncbi request reprint Immunotherapy for patients with malignant glioma: from theoretical principles to clinical applications
    Meng Yin Yang
    Division of Neurosurgery, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA 90095 6901, USA
    Expert Rev Neurother 6:1481-94. 2006
    ..We will also examine major new immunotherapy approaches that are being actively investigated to treat patients with malignant glioma, and identify some current and future research priorities in this area...
  12. ncbi request reprint NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain
    Robert M Prins
    Department of Surgery, Division of Neurosurgery, Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    J Immunol 177:8448-55. 2006
    ..Our results suggest that a better understanding of the cross-talk between DC and innate immune cells may provide improved methods to vaccinate patients with tumors located both systemically and within the CNS...
  13. ncbi request reprint Lentiviral vectors with CMV or MHCII promoters administered in vivo: immune reactivity versus persistence of expression
    Takahiro Kimura
    Department of Medicine, Division of Digestive Diseases, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA
    Mol Ther 15:1390-9. 2007
    ..These studies reveal that APC transduction by LVs could lead to immune reactivity (LV-CMV) or persistence of transgene expression (LV-MHCII), providing a relevant paradigm for vaccination and gene replacement approaches...
  14. pmc Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain
    Robert M Prins
    Department of Surgery, Division of Neurosurgery, David Geffen School of Medicine at UCLA, CHS 74 145, 10833 Le Conte Avenue, PO Box 956901, Los Angeles, CA 90095, USA
    Cancer Immunol Immunother 57:1279-89. 2008
    ..These studies demonstrate that peripheral tolerance to endogenous TAA can be overcome to treat tumors in the brain and suggest a novel trafficking paradigm for the homing of tumor-specific T cells that target CNS tumors...
  15. pmc Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate
    Robert M Prins
    N Engl J Med 359:539-41. 2008